Product Launch

Product Launch

Syntegrity

Pharma

CASE STUDY

The Defining Moment

A global pharmaceutical company had developed a new vaccine that was nearing launch, and knew they had to maximize patient access at time of launch. This required securing public and private coverage fast. One of the main challenges was that the vaccines business, recently acquired, still operated in isolation from the rest of the company and needed to quickly establish stronger working relationships with key functions like market access, while preserving its unique culture.

The Approach

Thirty-two people – directors, managers, and senior managers – gathered from across different parts of the organization, from marketing, health education,vaccines, access, regulatory, finance, to policy. Their challenge was to determine how to ensure that patients had optimal access to their novel vaccine at launch.

Together, the team produced a 12-point agenda that covered topics such as disease awareness, integration, customer needs, prioritization & workload. They mapped out scenarios for what would happen if they got the coverage they wanted,if they didn't, and so on. They produced strategic recommendations for coordinating campaigns across brands, for instituting better long-term planning to manage people's workload, and for creating a core team responsible for integrating the vaccines business with the broader human health division.

The Results

The team was able to produce a thoughtful plan – in a few days –that pulled together people from multiple businesses to execute rapidly. They were able to secure public and private coverage for the vaccine at unprecedented speed. The vaccine is now widely listed and used worldwide. It’s significant uptake at launch was noticed by global media and experts.

Back

Central Question:

“What new and innovative ideas will enable us to help oncology patients, while maximizing the launch and ongoing success of our new therapy?”

Central Question:

“What new and innovative ideas will enable us to help oncology patients, while maximizing the launch and ongoing success of our new therapy?”

The Results:

$4 Billion Blockbuster

join those in the know

Subscribe for all our latest Forbes articles, whitepapers, and more.

Thank you for subscribing to receive our latest insights via email. When we have news and information to share, we will reach out. In the meantime, you can explore some of our current content under the RESOURCES section here on our website. Enjoy!
Oops! Something went wrong while submitting the form